Home › Chronic Lymphocytic Leukemia › Kentucky
Chronic Lymphocytic Leukemia clinical trials in Kentucky
7 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in Kentucky.
Cities in Kentucky
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
RecruitingPhase 3
Ages 65 and older · All sexes · Updated Oct 2, 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- CommonSpirit Saint Joseph Hospital - Bardstown, Bardstown
- Commonwealth Cancer Center-Corbin, Corbin
- Saint Elizabeth Healthcare Edgewood, Edgewood
- and 5 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- University of Louisville, Brown Cancer Center, Louisville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06943872A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Saint Elizabeth Healthcare ( Site 0041), Edgewood
- Owensboro Medical Health System ( Site 0066), Owensboro
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06136559A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
- Norton Cancer Institute, St. Matthews Campus, Louisville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT06708897A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Saint Elizabeth Medical Center Edgewood, Edgewood
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 19, 2026 · NCT06588478The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Norton Cancer Institute, Louisville
RecruitingPhase 1/2
Ages 12 to 95 · All sexes · Updated Apr 15, 2026 · NCT04329728From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.